Plus Therapeutics, Inc. announced on May 14, 2025, the presentation of new data on its lead drug REYOBIQ™ at the Nuclear Medicine and Neurooncology Conference. The data highlighted clinical benefit and safety in the ReSPECT-LM clinical trial for patients with leptomeningeal metastases (LM).
The updated data showed multiple long-term LM survivors among patients who received multiple doses of REYOBIQ under compassionate use. RNA sequencing data also revealed early tumor apoptosis and activation of innate immune responses, followed by an increase in T cells and an adaptive immune response by Day 28.
Further details from the completed Phase 1 ReSPECT-LM dose escalation trial demonstrated a dose-dependent increase in absorbed radiation dose to the cranial subarachnoid space, reaching 253Gy in Cohort 5. Additionally, 5 of 7 patients with over 80% reduction in LM tumor cells in the cerebrospinal fluid survived at least one year post-treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.